Prazer Therapeutics
2:30 PM - 2:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Prazer Therapeutics is a Korean biotech company pioneering innovative small molecule therapeutics with a novel approach in targeted protein degradation (TPD). Prazer strives to overcome the limitations of first-generation TPD therapeutics with a proprietary TPD platform named SPiDEM (Selective Protein Degradation Enabling Moiety).
.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Songpa-gu
Company HQ Country:
Korea, Republic of
Year Founded:
2019
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
SPiDEM degraders targeting Tau and α-Synuclein
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
• Two (for strategic collaboration of in-house programs: SPiDEM degraders targeting Tau and α-Synuclein)
• Unlimited (for strategic collaboration to identify and develop novel targeted protein degraders by leveraging Prazer’s SPiDEM platform
Speaker
Transforming the Future of Targeted Protein Degradation (TPD) with SPiDEM
Prazer Therapeutics
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
